所有产品
  • 抗体
  • 试剂盒
  • 多肽
  • 蛋白
  • 生化试剂
  • 组织芯片
EN
cAMP/ cGMP/ Protein A/ β-Actin/ BSA/ Ddx4/ APOE/ TAU pT181/ TAU pT217/ Tau 1-441/ Aβ1-40/ Aβ1-42/ α-Syn/ GFAP/ IL/ CD/ 标记试剂盒/ GFP/ Flag/ 多肽合成服务/ /
抗体药类似物
当前位置：首页 > 产品中心 > 抗体 > 抗体药类似物
产品中心
Product Center
Research Grade Tralokinumab
All
Bioactivity
SDS-PAGE
  • Catalog： TD-HW632036
  • Clonality： Monoclonal
  • Application： ELISA, Bioactivity: FACS, Functional assay, Research in vivo
  • Synonyms： CAT-354, 1044515-88-9
  • 规格：
    询价
  • 价格：
    ¥100ug
定制服务咨询
详细相关信息
FAQ
实验方案
参考文献
  • Catalog No.
    TD-HW632036
  • Description
    Research Grade Tralokinumab(TD-HW632036) is ahuman monoclonalantibody detectingIL13inELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable forHuman.HighlightsMulti-Application— Validated across multiple applications.
  • Species reactivity
    Human
  • Applications
    ELISA, Bioactivity: FACS, Functional assay, Research in vivo
  • Host species
    Human
  • Isotype
    IgG4-lambda
  • Species
    Human
  • Clonality
    Monoclonal
  • Target
    IL13, NC30, Interleukin-13, IL-13
  • Endotoxin level
    Please contact with the lab for this information.
  • Purity
    >95% as determined by SDS-PAGE.
  • Purification
    Protein A/G purified from cell culture supernatant.
  • Accession
    P35225
  • Form
    Liquid
  • Storage buffer
    0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
  • Stability and Storage
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
  • Alternate Names
    CAT-354, 1044515-88-9
  • Background
    Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
  • Caption
    Detects Human IL13 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Tralokinumab.
  • Note
    For research use only. Not suitable for clinical or therapeutic use.